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It is commonly known that the insulin-like growth factor-I gene contains six exons that can
be differentially spliced to create multiple transcript variants. Further, there are two mutu-
ally exclusive leader exons each having multiple promoter sites that are variably used. The
mature IGF-I protein derived from the multiplicity of transcripts does not differ suggesting a
regulatory role for the various transcript isoforms.The variant forms possess different sta-
bilities, binding partners, and activity indicating a pivotal role for the isoforms. Research has
demonstrated differential expression of the IGF-I mRNA transcripts in response to steroids,
growth hormone, and developmental cues. Many studies of different tissues have focused
on assessing the presence, or putative action, of the transcript isoforms with little con-
sideration of the transcriptional mechanisms that generate the variants or the translational
use of the transcript isoforms. Control points for the latter include epigenetic regulation of
splicing and promoter usage in response to development or injury, RNA binding proteins
andmicroRNA effects on transcript stability, and preferential use of two leader exons by GH
and other hormones. This review will detail the current knowledge of the mechanical, hor-
monal, and developmental stimuli regulating IGF-1 promoter usage and splicing machinery
used to create the variants.
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For more than 60 years it has been known that the growth
hormone – IGF-I axis is critical for body growth and maintenance.
IGF-I is key to normal postnatal development: the absence of IGF-
I is characterized by poor prenatal growth in both the rat and
human (Fu et al., 2009). In addition to contributing to overall
growth, the IGF-GH axis is viewed as essential for the transition of
fetal to neonatal existence (Li et al., 1996). The essential role that
the IGF axis plays in growth and development is further under-
scored in mice null for IGF-I which have significantly impaired
growth while those null for IGF receptor die shortly after birth
(Baker et al., 1993; Liu et al., 1993). While the general concepts
of the interplay of GH and IGF-1 have been characterized, the
specifics surrounding the regulation of IGF-I expression are yet to
be detailed fully.
GENE STRUCTURE
The IGF-1 is a single gene consisting of six exons spanning
nearly 90 kb of genomic DNA. The exons are alternatively spliced
to generate multiple transcripts each encoding a different pre-
pro-IGF-I protein possessing variable signaling peptide leader
sequences. Yet after processing, all transcript isoforms give rise
to same mature 70-amino acid IGF-I peptide that uses the same
receptor (Holthuizen et al., 1991). The mature IGF-I peptide,
conserved across species (Shavlakadze et al., 2005), contains four
domains named for their similarity to those in insulin: the B-C-A-
D domains. The B domain is involved in IGF-I receptor (Gauguin
et al., 2008) and IGF binding protein (Magee et al., 1999) binding.
In addition to the highly conserved mature IGF-I, two other
protein forms have been described in the brain (Sara et al., 1989,
1993). The two forms represent post translational cleavage of the
IGF-I protein: one peptide is a 67 amino acid polypeptide lacking
the first three amino terminal amino acids. It is biologically active
in the brain, acts through the IGF-I receptor, and has low affinity
for IGF binding proteins. The glycyl-prolyl-glutamate tripeptide
cleavage product is also found in the human brain but appears
to act through glutamate receptors rather than the IGF-I receptor
(reviewed in Cacciatore et al., 2012).
The IGF-I pre-pro peptides differ in their leader, or signal,
sequences and in their carboxy-terminus. Incorporation of exon
1 or exon 2 is mutually exclusive with each serving as leader
sequences of the pre-pro-IGF-I peptide; the different leader exons
create different 5′UTRs (Figure 1). The pre-pro IGF-1 polypep-
tides undergo posttranscriptional proteolytic cleavage to remove
the leader and the E-peptide carboxy-terminus giving rise to the
70-amino acid, single chain mature IGF-I.
Transcripts containing exon 1 are referred to as Class 1 tran-
scripts whereas those containing exon 2 are referred to as Class 2
transcripts. Nearly all pre-pro peptides include 27 amino acids in
the signaling peptide derived from exon 3 with the remaining sig-
nal sequences derived from the inclusion of exon 1 or 2. A minority
of transcripts utilize a different transcription initiation site within
exon 3 generating a shorter signaling peptide of 22 amino acids
(Yang et al., 1995).
Exons 3 and 4 are invariant and encode the B, C, A, and D
domains of the mature IGF peptide; exon 4 encodes two thirds
of the mature IGF-I peptide. The carboxy-terminus constitutes
the E-peptide domain. All E-peptides include 16 amino acids
from exon 4 with variable sequences following depending upon
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FIGURE 1 |The IGF-1 gene structure. Splicing and exons in the rodent
gene generate distinct transcripts that vary in the 5′ and 3′ ends though the
mature peptide is invariant (A). Transcription initiation sites are denoted by
solid arrows above the exons: sites designated 1–4 are ∼382, 343, 245,
and 40 bases upstream of the 3′ end of exon 1, respectively and the two
sites in exon 2 ∼70 and 50 bases upstream of the 3′ end of exon 2. Sites
preferentially used are indicated with asterisks. Translation initiation is
denoted with open arrows below the exons.The human IGF-I transcripts are
depicted in (B).
inclusion/exclusion of exons 5 and 6. The E domain function
remains unclear (Matheny et al., 2010) although much specula-
tion surrounds this domain as it introduces the greatest variability
into the IGF transcripts and has challenged consistent nomen-
clature. Inclusion or exclusion of exon 5 into the pre-pro IGF-I
polypeptide gives rise to transcripts differing in E-peptide forms,
termination codons, polyadenylation sites, and 3′UTR’s (Shimatsu
and Rotwein, 1987; Shavlakadze et al., 2005).
SPLICING
In the rat, exclusion of exon 5 (that is, splicing exon 4 to exon 6)
creates the Ea peptide of 35 amino acids in length. Inclusion of
exon 5 (that is, splicing exon 4 to 5 and then 5 to 6) introduces 52
bases and a frame shift to generate an earlier stop codon in exon 6
thereby creating the Eb peptide of 41 amino acids; both Ea and Eb
have a common 3′UTR (Shimatsu and Rotwein, 1987). In rats, the
Eb transcripts account for∼10% of IGF-I transcript expression.
In contrast, the human Eb peptide is composed of only exons 4
and 5 (Rotwein et al., 1986) whereas the splice variant containing
exons 4, 5, and 6 is called the Ec peptide and is also referred to
as mechanogrowth factor (MGF) (Yang et al., 1996). The human
Eb splice variant is rarely detected in other species and then most
notably in mice with the murine exon 3, 4, 5 splice variant exist-
ing only for class 2 IGF-I isoforms (Shavlakadze et al., 2005). The
human Eb may reflect a poorly conserved 5′donor splice site in
the human IGF-1 gene causing the spliceosome to exclude exon
6 (Shavlakadze et al., 2005). The human exon 5 has a nucleolus
localization sequence (Weber et al., 2000) and a polyadenylation
site (Chew et al., 1995). In rodents, the Ea peptide, but not the Eb,
contains two potential N -glycosylation sites (Roberts et al., 1987)
though their role in processing and function of the IGF-I peptide
remains unknown to date. Human IGF-IEa peptides possess only
a single glycosylation site (Duguay et al., 1995).
An additional regulatory feature is the existence of a purine rich
splicing enhancer site downstream of exon 5 that is recognized
by the serine-arginine protein splicing factor-2/alternate splicing
factor. Occupancy of this enhancer facilitates recruitment to the
spliceosome and increases the efficiency of inclusion of exon 5 into
the transcript. Importantly, the serine-arginine protein splicing
factor-2/alternate splicing factor is activated by phosphorylation
or by cellular localization which may mediate tissue and hor-
monal specific splicing of the IGF-1 transcript (Smith et al., 2002)
consistent with the more limited expression of the Eb forms.
PROMOTER
While there exist no classical transcription start site elements for
IGF-1, the 5′UTR is highly conserved across human, rat, mouse,
sheep, and cattle genomes with basal promoter activity for exon 1
in the first 412 bp of the 5′ flanking region, and negative regulatory
elements beyond that (Lowe and Teasdale, 1992). In the rat exon
1 has 4 transcript start sites: ∼382 (site 1), ∼343 (site 2), ∼245
(site 3), and∼40 bp (site 4) upstream of the 3′ end of exon 1 with
sites 2 and 3 used most frequently (Adamo et al., 1991a; Simmons
et al., 1993; Yang et al., 1995; Wang et al., 1997). Two additional
minor start sites are found at ∼361 and ∼353 bp upstream of the
3′ end of exon 1 (Simmons et al., 1993). Usage of the four tran-
scription sites in exon 1 generate transcripts differing in signal
peptide structure. Sites 2 and 3 are upstream of a translation ini-
tiation codon and usage of either generates a 48 amino acid signal
sequence (Simmons et al., 1993; Yang et al., 1995) whereas usage
of site 3 is downstream of the translation initiation codon and the
signal sequence derived from this site is within exon 3 and is 22
amino acids long (Yang et al., 1995). An additional exon 1 trans-
lation initiation site exists in the human gene creating a 25 amino
acid signal sequence (Jansen et al., 1983).
Within the promoter region for exon 1, there exist DNAse I
hypersensitive sites (Thomas et al., 1995) that were uninfluenced
by GH suggesting complex transcriptional regulation of the gene.
Also described in the region were consensus sequences for hepa-
tocyte nuclear factor (HNF) transcription factor binding (Nolten
et al., 1996), CCAAT/enhancer binding proteins (C/EBP) (Nolten
et al., 1994), and GATA-binding protein motifs (Wang et al., 2000)
all perhaps involved in basal regulation of transcription. Other
enhancer elements within the promoter of exon 1 include an E
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box (5′-CAGCTG-3′). Binding of transcription factors, such as
MyoD1, to the E box increased transcription of class 1 transcripts
and is particularly important in muscle cell differentiation (McLel-
lan et al., 2006). Recently, using computational programs, addi-
tional cis elements were predicted to lie upstream of exon 1 includ-
ing sites for activator protein 1 (AP1) and interferon-consensus site
binding protein/interferon-regulating factor 8; binding was then
confirmed by electrophoretic mobility shift assays (Telgmann et al.,
2009).
Similarly, exon 2 utilizes two main transcription start sites∼50
and 70 bp upstream of the 3′ end of exon 2 (Adamo et al., 1991a;
Simmons et al., 1993; Yang et al., 1995) with the vast majority of
class 2 transcripts initiated at the site∼50 bp upstream of the 3′ end
of exon 2 (Adamo et al., 1991b). Both transcription initiation sites
are upstream of the two translational initiation codons thereby
generating two signal sequences of 32 or 22 amino acids although
the 32 amino acid leader sequence is preferentially utilized (Yang
et al., 1995).
3′UTR
There are four polyadenylation sites in the 3′UTR of exon 6 (Shi-
matsu and Rotwein, 1987) giving rise to various mRNA transcript
sizes: 0.8–1.2; 1.5–2.1; 7–7.5 kb (Lund et al., 1989); the size varia-
tion predominantly arises from the differences in polyadenylation
signal sequences in exon 6 (Jansen et al., 1992). The 0.8–1.2 tran-
script size represents either 1Ea or 2Ea and the 1.3 kb mRNA is
encoded by exons 1 or 2 and exons 3, 4, 5 (in the human the 1Eb
or 2Eb form). Studies of transcript stability indicate the 3′UTR
following exon 6 that generated 7–7.5 kb transcripts and rich in A
and U residues were less stable than the shorter 0.8–1.2 kb tran-
scripts (Hepler et al., 1990); that is, the longest transcripts with the
longest 3′UTR region have the shortest half-lives (Shimatsu and
Rotwein, 1987; Lund et al., 1989). Class 2 transcripts have greater
stability than class 1 (Wang et al., 2003).
Use of the polyadenylation sites in the 3′UTR affects IGF-I sta-
bility. Transcripts using the first polyadenylation site have a shorter
transcript size and are more highly expressed in the liver and have
greater stability (Foyt et al., 1991). Recent studies by Kawai et al.
(2010) investigated the mechanism behind the reduced stability
of the longer transcripts derived from the alternate polyadeny-
lation sites. They predicted that the longer 3′UTR could provide
more regulatory sites for RNA binding proteins, in particular RNA
binding proteins that initiate deadenylation, one of the initial
steps of RNA degradation. They determined that a gene regu-
lated by circadian rhythm, Noc, interacts with the 3′UTR of IGF-I
to destabilize the longer transcripts in a tissue-specific manner
to regulate expression of the IGF-I gene product (Kawai et al.,
2010).
3′UTR IN TRANSLATION
Beyond gene transcription, the regulation of gene expression pat-
terns occurs at translation. The regulation of translation, be it by
methylation or microRNA (miRNA) repression in the 3′ UTR, is
conserved across kingdoms with plants and animals using similar
mechanisms. In this way, despite the conservation of sequences
across species, unique and complex expression patterns can be
developed (Liang and Wang, 2012).
The efficiency of IGF-I transcript translation has been
described as being inversely related to the length of the 5′ UTR
(Yang et al., 1995) and in rats, for class 1 transcripts, those tran-
scripts that had initiated transcription at promoter site 4 were
more efficiently translated (Yang et al., 1995). Similarly, in cattle
the class 1 transcripts are translated more efficiently (fourfold)
than class 2 transcripts even though there were no elements
within the class 2 transcript that would be associated with reduced
translational efficiency (Wang et al., 2003).
More recently the 3′UTR and its role in regulating gene expres-
sion have come under scrutiny, most especially with the conser-
vation of translational control mechanisms across species. Bioin-
formatics approaches exploiting the ever expanding genome data-
bases have enabled the interrogation of 3′UTR with the objective
of identifying conserved sequences that may play a role in pro-
tein expression. For instance, binding sites for miRNAs or RNA
binding proteins, generally short sequences influenced by the sur-
rounding sequences, can govern secondary structure and possible
access to the transacting factors.
A comparative analysis of the human, mouse, rat, and dog
genomes uncovered 106 conserved common regulatory motifs in
the 3′UTRs that are likely involved in post transcriptional regu-
lation; a vast number of the motifs are associated with miRNAs
(Xie et al., 2005). miRNAs are ∼22 nucleotide non-coding RNAs
that act as post transcriptional regulators of gene expression and
are found in plants and animals (Winter et al., 2009). They act
to repress translation (“RNA silencing”) by binding to the 3′UTR
to repress or destabilize the target transcript. Secondary struc-
ture adjacent to common miRNA sites also modulates efficiency
of repression by miRNA (Liang and Wang, 2012). Approximately
25% of human miRNA genes lie in the introns of the pre-mRNA of
the genes themselves; by being in the same orientation of the genes
they control, they are likely processed from the introns enabling
the coordination between expression of the gene and translation of
the protein (Bartel, 2004, 2009). The 3′UTR of IGF-I contains 11 of
the top 50 conserved miRNA sites identified by Xie et al. (2005).
For example, the miRNA miR-206 preferentially targets IGF-I’s
3′UTR and miR-206 loss of function mutants exhibited acceler-
ated growth in tilapia and increased IGF-I expression in vivo (Yan
et al., 2013). Similarly the addition of miR-29 to cultures down
regulated IGF-I in myofibroblasts (Kwiecinski et al., 2012). Two
other miRNAs have been shown to interact with the 3′UTR and
reduce IGF-I translation, miR-1 and miR-320, while the binding
of miR-1 also reduced IGF-I stability (summarized by Lee and
Gorospe, 2010).
Another element in 3′UTRs that affects stability and translata-
bility are AU-rich elements (AREs). The protein HuR, a human
ELAV-like protein, binds to the ARE sequence (loosely defined
as AUUUA) (Myer et al., 1997; Brennan and Steitz, 2001) and is
viewed as a critical regulator of posttranscriptional gene expres-
sion. The ARE cis element for HuR is very common in 3′-UTR’s
(Gruber et al., 2011). Using a newly developed site to evaluate the
presence of AREs in genes (Gruber et al., 2011), it was determined
that IGF-I has 18 of the AUUUA motifs, with five showing high
conservation across all species. It is notable that the IGF-I 7–7.5 kb
transcripts are rich in A and U residues and have reduced stability
(Hepler et al., 1990) and both IGF-I and HuR appear to be essential
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for normal embryonic growth and development (Katsanou et al.,
2005).
As the understanding of translational regulation on gene
expression expands, the role and regulatory elements within the
conserved 3′UTR will assume greater importance in the overall
regulation of the IGF-1 gene.
BIOLOGICAL SIGNIFICANCE OF THE ISOFORMS
The biological significance of the isoforms remains unclear
although it has long been hypothesized that the use of exon 1 use
is the preferred autocrine/paracrine form (Sussenbach et al., 1992;
Gilmour, 1994) while exon 2 represents the secreted endocrine
form. Lending support to this is that class 2 transcripts possess
a typical signal peptide motif associated with efficient secretion
whereas class 1 transcripts have a longer signal peptide possibly
interfering with secretion (O’Sullivan et al., 2002a), likely through
myristoylation that directs the signal peptide to the endoplasmic
reticulum (Temmerman et al., 2010). Additional evidence comes
from class 2 transcripts being highly expressed in the liver, the pri-
mary source of circulating IGF-I (Sjögren et al., 1999; O’Sullivan
et al., 2002a). Further, class 1 transcripts have a diminished capac-
ity to bind binding proteins and are more mitogenic than the
class 2 mRNAs (LeRoith and Roberts, 1991) consistent with an
autocrine/paracrine role of the class 1 isoform.
Evidence blurring this categorization comes from overexpres-
sion studies. Transgenic pigs overexpressing class 1 transcripts in
the muscle had elevated circulating IGF-I (Pursel et al., 2004) and
cultured myoblasts overexpressing class 1 transcripts secreted IGF-
I into the media (Coleman et al., 1995). Further knocking out only
hepatic expression of IGF-I reduced but did not eliminate IGF-I
in circulation. Most importantly, the mice null for hepatic IGF-
I were not growth impaired indicating that autocrine/paracrine
expression is adequate for growth promotion (Sjögren et al., 1999).
In the mouse, both the glycosylated Ea and the non-glycosylated
Eb peptides facilitate binding of IGF-I to the extracellular
matrix regulating bioavailability lending further evidence for an
autocrine/paracrine action. The E-peptides are positively charged
because of a high basic amino acid content and deglycosylation
of Ea further improves its binding to the extracellular matrix by
an increase in the net peptide charge (Hede et al., 2012). In the
human, the pro-IGF-Eb peptide (containing exons 3, 4, 5) is not
secreted but accumulates in the nucleolus suggesting an autocrine
role for this isoform (Tan et al., 2002). The differential binding
affinities for extracellular matrix modulated by the E-peptides has
been suggested to be key in regulating secretion into circulation
(Temmerman et al., 2010).
PROMOTER ACTIVATION BY HORMONES
Even though the role of the various isoforms has not been fully
elucidated, their existence suggests biological relevance. Growth
hormone has been shown to directly stimulate transcription of
IGF-I in rats and mice (Mathews et al., 1986; Bichell et al., 1992)
and increases stability of IGF-I mRNA in sheep (O’Sullivan et al.,
2002b). Hepatic class 2 expression is highly regulated by GH with
GH preferentially driving exon 2 promoter usage in rats (Foyt
et al., 1992; Butler et al., 1994) and in cattle (Wang et al., 2003).
The regulation of class 2 transcripts by GH was seen also in lambs
immunized to suppress GH secretion; these lambs with reduced
GH also had significantly reduced class 2 transcripts (O’Sullivan
et al., 2002a). Yet it is also known that GH can increase 1 pro-
moter usage (Lin et al., 1998; Woelfle et al., 2003a). Cattle given a
single injection of GH increased both class 1 and class 2 hepatic
transcripts although class 2 transcript induction was double that
detected for class 1 (Wang et al., 2003).
The well known role of GH in driving IGF-I expression has led
to a dissection of the promoter region to uncover the cis-acting ele-
ments that control transcription and promoter usage in the IGF-1
gene. As noted above, characterizing DNAse I hypersensitive sites
in the exon 1 promoter failed to identify sites influenced by GH
(Thomas et al., 1995). Given the high expression of class 2 tran-
scripts in the liver, the absence of a direct GH effect on exon 1 was
not unexpected.
It is now recognized that GH exerts its effects through the
JAK/Stat pathway with activated Stat proteins translocating to the
nucleus and serving as transcription factors. In a series of studies
designed to characterize the binding of Stat proteins to the IGF-1
promoter, the Rotwein laboratory has uncovered more than 90
potential Stat5 binding sites in the 200 kb of DNA surrounding
the IGF-1 gene for rat, human, and mouse (Chia et al., 2006). The
researchers then focused on those most highly conserved sites to
undertake functional studies. Two distant, paired Stat5b sites exist
in the IGF-1 rat promoter, one pair lies in the second IGF-1 intron
(the site is referred to as HS7) and the other maps 73 kb 5′ of exon
1; the tandem HS7 site was most efficient at initiating transcrip-
tion in response to GH with a twofold transcription enhancement
relative to the occupancy of the tandem site upstream of exon 1
(Woelfle et al., 2003a,b; Chia et al., 2006). Their results demon-
strate that binding of Stat proteins, particularly Stat5b, mediates
the action of GH on promoter 2 of the mouse IGF-1. Further,
activation of HS7 site resulted in both class 1 and 2 transcripts
whereas activation of the site upstream of exon 1 only induced
class 1 transcripts (Chia et al., 2006). Other studies, Stat5b bind-
ing affinities were found to differ among the binding sequences,
with some sequences generating reduced transcriptional activa-
tion, and that the numerous Stat5b sites interact cooperatively to
modulate the transcriptional effects of GH (Varco-Merth et al.,
2012). In addition to the induction of Stat5 binding, treatment
with GH increases histone acetylation adjacent to each of the two
IGF-1 promoters. This chromatin modification is associated with
greater accessibility of the DNA for active transcription (Rotwein,
2012).
Both exon 1 and 2 promoters are estrogen responsive. Using a
chromatin immunoprecipitation (ChIP) assay, direct binding of
the estrogen receptor α at a site upstream of both exon 1 and exon
2 was detected (Hewitt et al., 2010). Interestingly, although ChIP
assays demonstrate direct binding of the estrogen receptor α to the
human IGF-1 promoter, there are no estrogen response element
(ERE) sequences present (Sasaki et al., 2008). In ovariectomized
mice treated with estrogen, class 1 transcripts were enhanced to a
greater degree than class 2 indicating exon 1 was more responsive
to estrogen activation (Ohtsuki et al., 2007) despite the absence
of EREs. In addition to the estrogen control of promoter usage,
an ERE in intron 3–4 was also seen (Hewitt et al., 2010) suggest-
ing a potential regulatory role in splicing. Supporting that view,
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studies of rats and humans demonstrate that systemic exposure to
steroids, androgens or estrogens, directly stimulate expression of
the Ea (exons 4, 6) and MGF/Ec (exons 4, 5, 6) transcript forms in
muscle (Gentile et al., 2010; Pöllänen et al., 2010) indicating a role
of steroids in the expression of the different isoforms. In mice, class
1 and class 2 transcripts changed in the uterus coordinated with the
estrous cycle but there were no concomitant changes in the kidney
or liver. In particular, estrogen preferentially increased class 1 tran-
scripts confirming the activity of the estrogen responsive element
in the promoter of exon 1 (Ohtsuki et al., 2007). Similarly rat IGF
mRNA is regulated by steroid hormones with estrogens enhance-
ment IGF mRNA in ovarian granulosa cells and the uterus whereas
dexamethasone represses IGF mRNA (Simmen, 1991).
TISSUE EXPRESSION
Most tissues are believed to use class 1 transcripts, though liver uses
both and hepatic class 2 transcripts are preferentially enhanced
during development (Adamo et al., 1991b; Lin et al., 1998); liver
is the source tissue for approximately 75% of the IGF-I protein in
circulation (Schwander et al., 1983) and in rat liver the class 1Ea
is the most abundant form representing 90% of the IGF expressed
(Lin and Oberbauer, 1998). Using a cre-loxP approach to create
Class 2 null mice, Temmerman et al. (2010) concluded that exon
2 use in the liver is not essential for normal growth and develop-
ment as the null mice showed normal development and postnatal
growth with normal IGF-I serum levels. They proposed that exon
1 fully compensated for the lack of exon 2. In contrast, mice null
for exon 3 were smaller and died shortly after birth – presumably
due to respiratory failure (Temmerman et al., 2010) confirming
the role of the mature IGF-I protein in the transition from uterine
to independent existence proposed by Li et al. (1996).
Wang et al. (2003) suggest that the ubiquitous presence of
both class 1 and class 2 isoforms in all mature bovine tissues
evaluated (ranging from adrenal gland to brain, fat hypothala-
mus kidney, liver lung mammary skeletal muscle, pituitary, rumen,
small intestine, spleen, and testis) indicates generic transcription
factors contribute to the express of IGF-I mRNA. Their supposi-
tion is confirmed by the presence of general regulatory elements
within the promoter. However, the level of expression varied with
some tissues expressing the two classes differentially, again, to be
expected based upon the promoter elements as discussed above. It
is notable however that in contrast to the ubiquitous expression of
both classes in all tissues in cattle (and sheep), the expression pat-
terns are more restricted in humans and rats with some tissues not
expressing one or the other class. Exon 2 transcripts in the rat are
not expressed in some tissues such as the heart, brain, and muscle
(Shemer et al., 1992). Different rat tissues appear to use different
transcription initiation sites within exon 1 again primarily using
the ∼343 (site 2) and ∼245 bp (site 3) upstream of the 3′ end of
exon 1 though the∼40 bp (site 4) site is constitutively used at low
levels (Shemer et al., 1992; Shavlakadze et al., 2005).
Human muscle express the Ea (exons 4, 6) and MGF/Ec (exons
4, 5, 6) transcript forms (Goldspink and Yang, 2004). Specifically,
the IEa and MGF/Ec/exon 4,5, 6 transcripts are expressed in resting
muscle, active muscle, damaged muscle, cardiac muscle especially
post ischemia, exercised tendon, and brain again particularly in
relation to ischemia; the expression in cardiac muscle and brain
following ischemic insult suggests a role for MGF/Ec/exon 4, 5, 6 in
the initiation of repair (reviewed in Dai et al., 2010). Interestingly,
aging diminishes the response of MGF/Ec/exon 4, 5, 6 to mechan-
ical stimulation suggesting reduced responsivity in the promoter
(reviewed in Dai et al., 2010).
As noted above, MGF is the human Ec form of the rat Eb. The
expression of MGF is linked to mechanical loading and stretching.
The role of MGF is that of a potent promoter of muscle hypertro-
phy and satellite cell activation. In contrast, within muscle, Ea is
implicated in proliferation and differentiation (reviewed by Philip-
pou et al., 2007). Thus many studies have evaluated the expression
and regulation of MGF in various muscle models as well as other
cell models in which loading is key. For example, in osteoblasts
subjected to mechanical loading, MGF expression was detected
only in loaded cells and not in control cells and the response of
MGF was much more rapid and transient than that of the more
highly expressed IEa form (Tang et al., 2006).
DEVELOPMENT
There are many changes in the IGF-I transcript abundance dur-
ing growth. Class 1 and class 2 increase during rat development
with increases in class 1 preceding that of class 2 (Adamo et al.,
1989, 1991b). During the perinatal and early postnatal develop-
mental periods in rats, hepatic class 1 and 2 isoforms differentially
changed in expression (Adamo et al., 1991b; Bichell et al., 1992;
Shoba et al., 1999) and mice (Lin and Oberbauer, 1998). Expres-
sion of the IGF in developing rat liver peaked at 4 weeks postnatal
declining at 6 weeks reflecting the ontogeny of the GH receptor
in the liver with the proportion of class 1Ea being most abun-
dant (Lin and Oberbauer, 1998); even though class 1Ea are more
abundant, in the rat, during postnatal development and on into
adulthood, exon 2 transcripts are more GH dependent (Lowe et al.,
1987; Adamo et al., 1989).
Within the growth plate, class 1Ea were the most abundant tran-
script with high expression during the active growth phase in the
proliferative and hypertrophic cell of the growth plate; by 6 weeks
expression had shifted to hypertrophic cells. Class 1Eb was also
expressed uniformly, albeit at low levels, across the growth plate
during early growth phases but shifted to hypertrophic predomi-
nance by the late growth stage. The shift in expression corresponds
to the maturation of the growth plate and demonstrates the
paracrine role of 1Ea (Lin and Oberbauer, 1999). Similar to the
findings of Foyt et al. (1991), the stability of class 1Ea in growth
plate chondrocytes was greatly reduced relative to that of the class
1Eb or class 2Ea transcripts; the stability did not change with
age indicating that stability in the growth plate was not devel-
opmentally regulated (Laugero and Oberbauer, 2000). There were
however, translational differences of the transcripts with increas-
ing age in growth plate chondrocytes (Laugero and Oberbauer,
2000).
Both IGF-1 promoters respond to fasting, diabetes, and caloric
intake with the class 2 promoter more responsive to those fac-
tors (Adamo et al., 1989, 1991b). For example, hepatic class
1 and 2 isoforms were decreased in unfed or diabetic rats
(Adamo et al., 1991b). Maternal nutrient deprivation results in
intrauterine growth restriction (IUGR) of the offspring. Neonates
from such deprivation have deficiencies in postnatal circulating
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IGF-I. Additionally, the IUGR has potential long term epigenetic
consequences. Neonatal rats with IUGR exhibited decreased IGF-I
promoter 1 usage at day 0 reflecting hypermethylation of spe-
cific CpG islands (Fu et al., 2009). Although IGF-I expression was
restored by day 21, the CpG islands were still hypermethylated and
class 1B transcripts were still reduced (Fu et al., 2009). Promoter 2
was also hypermethylated showing reduced usage that persisted to
day 21 (Fu et al., 2009). Thus, maternal nutrient deprivation can
alter usage of the neonate’s IGF-1 promoters.
Given the essential association of IGF-I and neonatal devel-
opment, researchers have predicted that mutations in the IGF-1
gene may correspond to small stature typical of IUGR. A novel
splicing mutation in intron 4 of the IGF gene results in aberrant
splicing and the exclusion of exon 4. The resulting truncated 1Ea
transcript contains primarily the B domain sequences predicted to
compete with the normal protein at the receptor potentially acting
as dominant negative mutation (Fuqua et al., 2012). Individuals
heterozygous for this mutation exhibit short stature.
Mutations in the polyadenylation site of the 3′UTR in exon 6
have been associated with IGF-I deficiency and with symptoms
of IUGR such as short stature and neurological deficits (Bona-
pace et al., 2003) though other investigators have questioned the
causality of the mutation in the short stature phenotype. Polymor-
phisms upstream of the core polyadenylation site in the 3′UTR in
exon 6 were characterized in small for gestational aged children
(IUGR) (Coutinho et al., 2007). The core polyadenylation site is
important in correctly directing the endonucleolytic cleavage of
pre-mRNA and the addition of the poly(A) tail. The investiga-
tors concluded that there exists polymorphisms and the region
is critical for proper processing of the pre-mRNA, but none of
the changes were causal in children born small for gestational
age.
Epigenetic modification of genes, as a result of environmen-
tal perturbations or normal growth and development patterns, is
known to regulate transcription. Epigenetic methylation of the
IGF-1 promoter and the 5′UTR represses transcription DNA (Fu
et al., 2009). In contrast to the promoter, DNA methylation in
3′UTR increases transcription (Fu et al., 2009).
An elegant experiment in a rat model explored the role and
mechanism of exon use of IGF-I in response to traumatic brain
injury (Schober et al., 2012). As previously noted, inclusion of exon
5 is elevated in response to tissue insult. The investigators hypoth-
esized that promoter usage and inclusion of exon 5 in the IGF-I
transcripts reflected changes in the accessibility of the DNA. In
their study, Eb was transiently elevated concomitant with a reduc-
tion of methylation surrounding the purine rich splicing enhancer
site downstream of exon 5; when Eb levels decreased, methylation
of the enhancer site was restored. Similarly, histone modifications
were observed with the increased abundance of the Eb transcripts
and those modifications were reversed when Eb transcripts were
restored to normal. The promoter for exon 1 was hypermethylated
in response to injury whereas the promoter for exon 2 had a histone
modification profile consistent with enhanced transcription. IGF-I
Eb is expressed most highly in the brain during early development
after which quantities declined (Beresewicz et al., 2010) suggesting
developmental regulation of the splicing machinery. The studies
of Schober et al. (2012) that showed epigenetic modifications of
the DNA was associated with differential promoter and exon usage
lend support to this hypothesis.
Developmental regulation of the transcription factors that bind
the IGF promoter also contribute to developmental IGF profiles.
Croci et al. (2010) analyzed genomic sequence databases for genes
having binding sites for the developmental transcription factor,
early B-cell factor (EBF). They determined that IGF-I had two such
binding sites, one of which (EBF-2) was highly conserved across
species (mouse to man) and found in the 5′ promoter region of
exon 1. Through functional studies the researchers determined
that EBF highly regulates the transcription of locally produced
IGF-I in the brain in a developmental fashion (Croci et al., 2010).
The absence of IGF-I at defined stages of development contributes
to neuronal pruning that occurs postnatal.
Yet another developmental regulatory mechanism is seen in
miRNA. As noted above, the presence of miRNA binding sites in
the 3′UTR are potential targets of growth regulation. For example,
in tilapia, loss of function miR-206 mutants exhibited enhanced
growth (Yan et al., 2013).
AGING
Damaged or exercised muscle preferentially upregulates expres-
sion of MGF transcript form though in terms of absolute IGF
isoform expression, the Ea form predominates (Hameed et al.,
2004b; Hill and Goldspink, 2004). The MGF isoform is expressed
in resting muscle, active muscle, damaged muscle, cardiac muscle
especially post ischemia, exercised tendon, and brain again partic-
ularly in relation to ischemia. The expression following ischemic
insult suggests a role for MGF in the initiation of repair (reviewed
in Dai et al., 2010). Human MGF is expressed earlier than Ea
during bouts of exercise (Haddad and Adams, 2002). Following
muscle damage, a similar burst of MGF expression is observed
which is then followed a more sustained expression of Ea (Hill
and Goldspink, 2004). Mature and aged rats have a reduced
capacity to express MGF when compared with young rats in a
stretching and loading muscle system and the amount of MGF
in aged rats reached a plateau whereas the young animals con-
tinued to rise in expression (Owino et al., 2001). MGF responds
more rapidly to GH stimulation in myoblast cultures than 1Ea
expression (Imanaka et al., 2008). Taken together the data indicate
some mechanoresponse element in the promoter of IGF-1 that is
coordinately regulated by GH.
Muscle IGF-I also exhibits an aging response to GH. Muscle
biopsies taken from young men given recombinant GH who were
either exercising or sedentary expressed both class 1 and class 2
isoforms with class 1Ea predominating. In fact, for the young
men, the exercise or GH regimens evinced no effect on IGF-1
promoter usage or splicing (Aperghis et al., 2009). This differs
from findings in aged men: class 1Ea increased in the muscles of
elderly men given exogenous recombinant GH (Hameed et al.,
2004a). The differential response is likely associated with declin-
ing GH in advancing age suggesting differential response to GH in
GH-replete and GH-deficient physiological states.
Variable circulating GH impacting IGF-I isoform expression
was tested in transgenic mice exposed to chronic, mildly elevated
GH. These animals downregulated class 2Ea but not class 1Ea tran-
script expression (Lin et al., 1998). In mature mice, acute induction
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of high circulating GH via transgene activation resulted in rapid,
transient induction of class 1Ea while class 2Ea declined. Thus,
chronic low level elevated GH downregulated class 2 mRNA and
when those mice were exposed to even greater GH levels class 2
was further reduced confirming that class 2 transcripts are most
sensitive to GH stimulation and subject to down regulation. The
persistence of class 1 transcripts to maintain responsiveness to GH
despite elevated GH may reflect class 1 mediating GH’s pulsatile
effects as well as being consistent with Stat5b binding to the site
upstream of exon 1 driving class 1 expression.
The extensive number of miRNAs identified in posttranscrip-
tional regulation suggests a role in aging (Inukai and Slack, 2013).
The known miRNA sites in the 3′UTR of the transcript iso-
forms support involvement of miRNA in regulating IGF-I during
aging. As evidence of this, in liver fibrosis, miRNA-29 is lost and
IGF-I rises promoting collagen expression. Using cultured hepatic
stellate cells to model the fibrosis arising from injury, providing
miR-29 to these cultures down regulates IGF-I reducing formation
of collagen (Kwiecinski et al., 2012).
CONCLUDING REMARKS
The nuances of the various IGF-I transcripts are being slowly
uncovered such as the dissection of the promoter region and the
characterization of the 3′UTR. Yet, despite decades of analysis the
function of some components of IGF-I transcripts remain to be
discovered. The recent advances in genome wide sequencing has
opened up new avenues to evaluate gene transcription and transla-
tional regulation. This will be particularly valuable to uncovering
the mysteries behind the complex expression patterns seen for the
IGF-1 gene.
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